FY2025 EPS Estimates for CRSP Cut by Cantor Fitzgerald

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for shares of CRISPR Therapeutics in a report issued on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings per share of ($6.91) for the year, down from their previous estimate of ($5.08). Cantor Fitzgerald has a "Neutral" rating on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

Several other equities analysts also recently issued reports on the stock. Stifel Nicolaus cut their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a report on Thursday, February 13th. Needham & Company LLC restated a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Chardan Capital cut their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Citigroup dropped their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $74.40.

CRISPR Therapeutics Stock Down 5.0 %

Shares of CRSP traded down $2.52 during mid-day trading on Friday, hitting $47.91. 2,671,174 shares of the company traded hands, compared to its average volume of 2,550,435. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10. The company has a market capitalization of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. The business has a 50 day moving average of $42.25 and a 200 day moving average of $46.06.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CRSP. Highline Wealth Partners LLC purchased a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $39,000. Western Pacific Wealth Management LP lifted its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after buying an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at approximately $40,000. Darwin Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter valued at approximately $43,000. Finally, Eastern Bank acquired a new position in CRISPR Therapeutics in the 3rd quarter valued at $70,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.